| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Defects, Congenital | 65 | 2020 | 596 | 7.130 |
Why?
|
| Fontan Procedure | 33 | 2022 | 129 | 5.710 |
Why?
|
| Heart Ventricles | 35 | 2020 | 738 | 4.070 |
Why?
|
| Cardiac Surgical Procedures | 38 | 2021 | 450 | 3.770 |
Why?
|
| Hypoplastic Left Heart Syndrome | 27 | 2021 | 138 | 3.600 |
Why?
|
| Infant, Newborn | 76 | 2022 | 2455 | 2.320 |
Why?
|
| Infant | 73 | 2021 | 2891 | 1.840 |
Why?
|
| Nitric Oxide | 13 | 2006 | 382 | 1.720 |
Why?
|
| Child | 72 | 2022 | 6405 | 1.640 |
Why?
|
| Child, Preschool | 58 | 2021 | 3187 | 1.570 |
Why?
|
| Pulmonary Artery | 16 | 2018 | 323 | 1.560 |
Why?
|
| Ductus Arteriosus, Patent | 3 | 2022 | 38 | 1.470 |
Why?
|
| Echocardiography | 20 | 2018 | 515 | 1.430 |
Why?
|
| Postoperative Complications | 25 | 2019 | 1615 | 1.400 |
Why?
|
| Heart Transplantation | 14 | 2018 | 328 | 1.300 |
Why?
|
| Health Status | 10 | 2017 | 429 | 1.280 |
Why?
|
| Hypertension, Pulmonary | 11 | 2019 | 232 | 1.280 |
Why?
|
| Ventricular Function | 8 | 2017 | 93 | 1.230 |
Why?
|
| Cardiac Catheterization | 15 | 2019 | 419 | 1.180 |
Why?
|
| Humans | 163 | 2022 | 68618 | 1.170 |
Why?
|
| Transposition of Great Vessels | 3 | 2018 | 51 | 1.150 |
Why?
|
| Norwood Procedures | 9 | 2018 | 61 | 1.130 |
Why?
|
| Treatment Outcome | 53 | 2021 | 7029 | 1.120 |
Why?
|
| Male | 106 | 2021 | 37321 | 1.060 |
Why?
|
| Natriuretic Peptide, Brain | 7 | 2021 | 101 | 1.050 |
Why?
|
| Female | 110 | 2022 | 38074 | 1.040 |
Why?
|
| Methylprednisolone | 6 | 2021 | 99 | 0.990 |
Why?
|
| Adolescent | 51 | 2022 | 8912 | 0.970 |
Why?
|
| Cardiopulmonary Bypass | 9 | 2020 | 250 | 0.960 |
Why?
|
| Preoperative Care | 10 | 2018 | 275 | 0.930 |
Why?
|
| Quality of Life | 9 | 2020 | 1515 | 0.920 |
Why?
|
| Sildenafil Citrate | 5 | 2021 | 23 | 0.890 |
Why?
|
| Ventricular Function, Left | 9 | 2022 | 481 | 0.870 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2022 | 15 | 0.850 |
Why?
|
| Follow-Up Studies | 31 | 2020 | 3259 | 0.840 |
Why?
|
| Vasodilator Agents | 7 | 2019 | 138 | 0.840 |
Why?
|
| Health Information Systems | 1 | 2022 | 18 | 0.830 |
Why?
|
| Exercise Test | 8 | 2021 | 242 | 0.820 |
Why?
|
| Myocardial Contraction | 4 | 2017 | 383 | 0.820 |
Why?
|
| Retrospective Studies | 38 | 2022 | 7277 | 0.800 |
Why?
|
| Graft Rejection | 6 | 2017 | 458 | 0.800 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 3 | 2019 | 25 | 0.790 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2022 | 34 | 0.790 |
Why?
|
| Arterial Switch Operation | 2 | 2018 | 10 | 0.780 |
Why?
|
| Clinical Trials as Topic | 6 | 2020 | 848 | 0.770 |
Why?
|
| Cross-Sectional Studies | 23 | 2022 | 2279 | 0.760 |
Why?
|
| Biomarkers | 11 | 2021 | 1593 | 0.760 |
Why?
|
| Rural Population | 2 | 2022 | 398 | 0.740 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 234 | 0.730 |
Why?
|
| Research Support as Topic | 1 | 2020 | 58 | 0.720 |
Why?
|
| Heart Bypass, Right | 7 | 2017 | 30 | 0.720 |
Why?
|
| Heart Septal Defects, Atrial | 4 | 2011 | 37 | 0.710 |
Why?
|
| Medically Underserved Area | 1 | 2020 | 85 | 0.710 |
Why?
|
| Heart Failure | 6 | 2022 | 1180 | 0.710 |
Why?
|
| Biological Products | 1 | 2021 | 78 | 0.690 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 232 | 0.680 |
Why?
|
| Length of Stay | 13 | 2019 | 780 | 0.650 |
Why?
|
| Hemodynamics | 10 | 2015 | 705 | 0.650 |
Why?
|
| Antiviral Agents | 1 | 2021 | 211 | 0.640 |
Why?
|
| Prospective Studies | 28 | 2021 | 3705 | 0.640 |
Why?
|
| Time Factors | 26 | 2021 | 4655 | 0.630 |
Why?
|
| Risk Factors | 27 | 2019 | 5731 | 0.620 |
Why?
|
| Blalock-Taussig Procedure | 5 | 2018 | 20 | 0.620 |
Why?
|
| Siblings | 1 | 2018 | 34 | 0.620 |
Why?
|
| Graft Survival | 3 | 2017 | 465 | 0.610 |
Why?
|
| Pediatrics | 2 | 2020 | 341 | 0.600 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2021 | 189 | 0.590 |
Why?
|
| Enalapril | 6 | 2019 | 86 | 0.590 |
Why?
|
| Anastomosis, Surgical | 6 | 2011 | 104 | 0.580 |
Why?
|
| Chest Tubes | 2 | 2016 | 18 | 0.570 |
Why?
|
| Oxygen Consumption | 8 | 2021 | 258 | 0.550 |
Why?
|
| Heart Septal Defects, Ventricular | 3 | 2011 | 59 | 0.550 |
Why?
|
| United States | 21 | 2022 | 7367 | 0.540 |
Why?
|
| Chylothorax | 1 | 2016 | 11 | 0.540 |
Why?
|
| Infant, Premature | 6 | 2019 | 284 | 0.530 |
Why?
|
| Forecasting | 1 | 2017 | 277 | 0.530 |
Why?
|
| Risk Assessment | 14 | 2017 | 2007 | 0.530 |
Why?
|
| Piperazines | 2 | 2012 | 206 | 0.520 |
Why?
|
| Neurodevelopmental Disorders | 3 | 2021 | 50 | 0.510 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2017 | 202 | 0.510 |
Why?
|
| Indomethacin | 1 | 2015 | 107 | 0.500 |
Why?
|
| Heart Atria | 4 | 2011 | 206 | 0.490 |
Why?
|
| Marfan Syndrome | 3 | 2020 | 42 | 0.490 |
Why?
|
| Abnormalities, Multiple | 5 | 2008 | 109 | 0.490 |
Why?
|
| HLA-C Antigens | 1 | 2014 | 8 | 0.480 |
Why?
|
| HLA-DQ Antigens | 1 | 2014 | 19 | 0.480 |
Why?
|
| Glucocorticoids | 5 | 2019 | 222 | 0.480 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2021 | 277 | 0.480 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 38 | 0.470 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 117 | 0.470 |
Why?
|
| Double-Blind Method | 14 | 2022 | 1738 | 0.460 |
Why?
|
| Sulfones | 2 | 2012 | 45 | 0.460 |
Why?
|
| Vasodilation | 3 | 2006 | 85 | 0.450 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2015 | 240 | 0.450 |
Why?
|
| Incidence | 11 | 2020 | 1603 | 0.440 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2016 | 296 | 0.440 |
Why?
|
| Administration, Inhalation | 11 | 2006 | 187 | 0.440 |
Why?
|
| Fibrinolytic Agents | 1 | 2016 | 377 | 0.430 |
Why?
|
| Hospital Mortality | 8 | 2016 | 384 | 0.430 |
Why?
|
| Palliative Care | 6 | 2018 | 271 | 0.420 |
Why?
|
| Linear Models | 7 | 2014 | 521 | 0.420 |
Why?
|
| Postoperative Care | 4 | 2011 | 163 | 0.420 |
Why?
|
| Young Adult | 16 | 2022 | 5717 | 0.410 |
Why?
|
| Stroke Volume | 6 | 2022 | 586 | 0.410 |
Why?
|
| Alprostadil | 1 | 2012 | 20 | 0.410 |
Why?
|
| Child Development | 4 | 2021 | 102 | 0.400 |
Why?
|
| Exercise Tolerance | 3 | 2020 | 75 | 0.400 |
Why?
|
| Multivariate Analysis | 12 | 2016 | 1046 | 0.390 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 5 | 2010 | 20 | 0.390 |
Why?
|
| Developmental Disabilities | 3 | 2020 | 119 | 0.390 |
Why?
|
| Cardiotonic Agents | 6 | 2019 | 71 | 0.390 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 82 | 0.390 |
Why?
|
| Vasoconstrictor Agents | 2 | 2017 | 107 | 0.380 |
Why?
|
| Situs Inversus | 2 | 2007 | 13 | 0.370 |
Why?
|
| Prenatal Diagnosis | 2 | 2010 | 73 | 0.360 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2018 | 536 | 0.350 |
Why?
|
| Postoperative Period | 11 | 2020 | 238 | 0.350 |
Why?
|
| Survival Rate | 9 | 2020 | 1056 | 0.350 |
Why?
|
| Milrinone | 5 | 2019 | 12 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2020 | 931 | 0.340 |
Why?
|
| Down Syndrome | 1 | 2010 | 120 | 0.340 |
Why?
|
| Pulmonary Circulation | 8 | 2008 | 79 | 0.330 |
Why?
|
| Disorders of Sex Development | 1 | 2009 | 8 | 0.330 |
Why?
|
| Anthropometry | 2 | 2020 | 64 | 0.330 |
Why?
|
| Tissue and Organ Procurement | 3 | 2017 | 164 | 0.330 |
Why?
|
| Blood Gas Analysis | 3 | 2005 | 41 | 0.320 |
Why?
|
| Ventricular Pressure | 3 | 2019 | 82 | 0.320 |
Why?
|
| Prognosis | 10 | 2021 | 2093 | 0.310 |
Why?
|
| Vitamin D | 1 | 2012 | 516 | 0.310 |
Why?
|
| Surveys and Questionnaires | 14 | 2020 | 2800 | 0.310 |
Why?
|
| Diastole | 5 | 2022 | 161 | 0.310 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 504 | 0.300 |
Why?
|
| Age Factors | 12 | 2019 | 1864 | 0.300 |
Why?
|
| Models, Biological | 4 | 2020 | 981 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2020 | 1745 | 0.300 |
Why?
|
| Premedication | 1 | 2007 | 49 | 0.300 |
Why?
|
| Blood Pressure | 5 | 2015 | 1451 | 0.300 |
Why?
|
| Tetralogy of Fallot | 1 | 2007 | 43 | 0.300 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2007 | 36 | 0.300 |
Why?
|
| Patient Selection | 5 | 2020 | 592 | 0.300 |
Why?
|
| Propranolol | 1 | 2007 | 103 | 0.300 |
Why?
|
| Drug Administration Schedule | 5 | 2020 | 567 | 0.280 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2017 | 22 | 0.280 |
Why?
|
| Oxygen | 7 | 2006 | 386 | 0.270 |
Why?
|
| Anaerobic Threshold | 2 | 2017 | 13 | 0.270 |
Why?
|
| Overweight | 2 | 2022 | 186 | 0.270 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2006 | 32 | 0.270 |
Why?
|
| Endpoint Determination | 3 | 2018 | 82 | 0.270 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 498 | 0.270 |
Why?
|
| Databases, Factual | 3 | 2019 | 622 | 0.270 |
Why?
|
| Pulmonary Wedge Pressure | 5 | 2015 | 102 | 0.270 |
Why?
|
| Proportional Hazards Models | 7 | 2018 | 792 | 0.260 |
Why?
|
| Vena Cava, Superior | 2 | 2005 | 41 | 0.260 |
Why?
|
| Cardiac Output, Low | 5 | 2012 | 52 | 0.260 |
Why?
|
| Myocarditis | 3 | 2021 | 49 | 0.260 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2006 | 72 | 0.260 |
Why?
|
| Pulmonary Atresia | 2 | 2003 | 6 | 0.260 |
Why?
|
| Canada | 4 | 2020 | 267 | 0.260 |
Why?
|
| Logistic Models | 7 | 2017 | 1420 | 0.250 |
Why?
|
| Heart Arrest | 1 | 2006 | 113 | 0.250 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2005 | 7 | 0.250 |
Why?
|
| Vasopressins | 1 | 2005 | 33 | 0.250 |
Why?
|
| Gestational Age | 5 | 2019 | 389 | 0.240 |
Why?
|
| Ontario | 2 | 2017 | 24 | 0.240 |
Why?
|
| Ventricular Dysfunction | 2 | 2017 | 15 | 0.240 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2005 | 141 | 0.230 |
Why?
|
| Chi-Square Distribution | 5 | 2011 | 546 | 0.230 |
Why?
|
| Ebstein Anomaly | 1 | 2003 | 2 | 0.220 |
Why?
|
| Infant, Premature, Diseases | 2 | 2021 | 85 | 0.220 |
Why?
|
| Neonatal Screening | 1 | 2003 | 43 | 0.220 |
Why?
|
| Heart Rate | 4 | 2021 | 568 | 0.210 |
Why?
|
| Tissue Donors | 2 | 2014 | 195 | 0.210 |
Why?
|
| Injections, Intravenous | 2 | 2019 | 215 | 0.210 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2015 | 189 | 0.210 |
Why?
|
| Vascular Resistance | 5 | 2006 | 179 | 0.200 |
Why?
|
| Disease-Free Survival | 4 | 2018 | 349 | 0.200 |
Why?
|
| Fentanyl | 1 | 2022 | 26 | 0.200 |
Why?
|
| Heart Function Tests | 2 | 2012 | 33 | 0.200 |
Why?
|
| Phosphodiesterase Inhibitors | 2 | 1999 | 28 | 0.200 |
Why?
|
| Carbon Dioxide | 1 | 2001 | 78 | 0.200 |
Why?
|
| Hypotension | 1 | 2021 | 74 | 0.190 |
Why?
|
| Echocardiography, Doppler, Color | 4 | 2011 | 33 | 0.190 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 244 | 0.190 |
Why?
|
| Critical Illness | 1 | 2022 | 191 | 0.190 |
Why?
|
| Perinatal Care | 1 | 2020 | 17 | 0.190 |
Why?
|
| Cohort Studies | 7 | 2021 | 2358 | 0.190 |
Why?
|
| Capacity Building | 1 | 2020 | 17 | 0.180 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1054 | 0.180 |
Why?
|
| Child Health | 1 | 2020 | 15 | 0.180 |
Why?
|
| South Carolina | 7 | 2017 | 2752 | 0.180 |
Why?
|
| Education, Continuing | 1 | 2020 | 28 | 0.180 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2020 | 27 | 0.180 |
Why?
|
| Metoclopramide | 1 | 2020 | 21 | 0.180 |
Why?
|
| Adult | 14 | 2022 | 21403 | 0.180 |
Why?
|
| Simuliidae | 1 | 2000 | 1 | 0.180 |
Why?
|
| Bacillus thuringiensis | 1 | 2000 | 2 | 0.180 |
Why?
|
| Pest Control, Biological | 1 | 2000 | 2 | 0.180 |
Why?
|
| Odds Ratio | 5 | 2016 | 880 | 0.170 |
Why?
|
| Research Design | 3 | 2013 | 729 | 0.170 |
Why?
|
| Cytokines | 3 | 2013 | 866 | 0.170 |
Why?
|
| Intraoperative Period | 1 | 2019 | 62 | 0.170 |
Why?
|
| Echocardiography, Doppler | 1 | 2019 | 87 | 0.170 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 1999 | 10 | 0.170 |
Why?
|
| Atenolol | 2 | 2020 | 20 | 0.170 |
Why?
|
| Coronary Disease | 2 | 2014 | 358 | 0.170 |
Why?
|
| Body Weight | 4 | 2020 | 554 | 0.170 |
Why?
|
| Losartan | 2 | 2020 | 45 | 0.170 |
Why?
|
| Enterocolitis, Necrotizing | 2 | 2017 | 37 | 0.170 |
Why?
|
| Exercise | 3 | 2021 | 658 | 0.170 |
Why?
|
| Patient Care | 1 | 2019 | 61 | 0.170 |
Why?
|
| Child Behavior Disorders | 1 | 2019 | 69 | 0.170 |
Why?
|
| Electrocardiography | 3 | 2021 | 601 | 0.160 |
Why?
|
| Ligation | 2 | 2017 | 83 | 0.160 |
Why?
|
| Aorta, Thoracic | 3 | 2015 | 211 | 0.160 |
Why?
|
| Parents | 3 | 2014 | 312 | 0.160 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 1999 | 435 | 0.160 |
Why?
|
| Reproducibility of Results | 8 | 2017 | 2077 | 0.160 |
Why?
|
| Regression Analysis | 3 | 2019 | 737 | 0.160 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2019 | 92 | 0.160 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2021 | 83 | 0.160 |
Why?
|
| Allografts | 2 | 2015 | 63 | 0.160 |
Why?
|
| Enteral Nutrition | 2 | 2017 | 157 | 0.150 |
Why?
|
| Pedigree | 1 | 2018 | 159 | 0.150 |
Why?
|
| Amiodarone | 1 | 2018 | 21 | 0.150 |
Why?
|
| Myocardium | 2 | 2015 | 1204 | 0.150 |
Why?
|
| Infant Mortality | 2 | 2015 | 59 | 0.150 |
Why?
|
| Nervous System | 2 | 2015 | 45 | 0.150 |
Why?
|
| Brain Injuries | 1 | 2021 | 268 | 0.150 |
Why?
|
| Patient Compliance | 1 | 2020 | 402 | 0.150 |
Why?
|
| Critical Care | 2 | 2010 | 263 | 0.150 |
Why?
|
| Gastroesophageal Reflux | 1 | 2020 | 318 | 0.150 |
Why?
|
| Inpatients | 1 | 2019 | 208 | 0.150 |
Why?
|
| Purines | 2 | 2012 | 39 | 0.150 |
Why?
|
| Heparin | 1 | 1998 | 205 | 0.150 |
Why?
|
| Cardiologists | 1 | 2017 | 9 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 39 | 0.140 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2009 | 79 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.140 |
Why?
|
| Treatment Failure | 2 | 2015 | 216 | 0.140 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 172 | 0.140 |
Why?
|
| Administration, Oral | 2 | 2019 | 411 | 0.140 |
Why?
|
| Anesthesia, General | 1 | 2016 | 86 | 0.130 |
Why?
|
| Mitral Valve Stenosis | 1 | 1996 | 15 | 0.130 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2015 | 4 | 0.130 |
Why?
|
| Dobutamine | 1 | 2015 | 25 | 0.130 |
Why?
|
| Atrial Function, Right | 1 | 2015 | 2 | 0.130 |
Why?
|
| Coronary Artery Disease | 2 | 2015 | 696 | 0.130 |
Why?
|
| Intensive Care Units | 4 | 2013 | 344 | 0.130 |
Why?
|
| Drainage | 1 | 2016 | 133 | 0.130 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2015 | 9 | 0.130 |
Why?
|
| Pulmonary Veins | 2 | 2011 | 56 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2019 | 374 | 0.130 |
Why?
|
| Lactulose | 1 | 2015 | 13 | 0.130 |
Why?
|
| Mannitol | 1 | 2015 | 25 | 0.130 |
Why?
|
| Infant Formula | 1 | 2015 | 24 | 0.130 |
Why?
|
| Dried Blood Spot Testing | 1 | 2015 | 4 | 0.130 |
Why?
|
| Aorta | 2 | 2014 | 316 | 0.130 |
Why?
|
| Perioperative Care | 1 | 2016 | 100 | 0.120 |
Why?
|
| Urinalysis | 1 | 2015 | 27 | 0.120 |
Why?
|
| Apolipoprotein E2 | 1 | 2014 | 8 | 0.120 |
Why?
|
| Coronary Vessels | 2 | 2015 | 313 | 0.120 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 95 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 186 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 1465 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 191 | 0.120 |
Why?
|
| Aortic Aneurysm | 1 | 2014 | 77 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 219 | 0.120 |
Why?
|
| Intraoperative Care | 2 | 2011 | 91 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2014 | 82 | 0.120 |
Why?
|
| Syndrome | 4 | 2007 | 255 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2011 | 242 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 1 | 1997 | 364 | 0.110 |
Why?
|
| Prevalence | 3 | 2014 | 1619 | 0.110 |
Why?
|
| Milk, Human | 1 | 2015 | 147 | 0.110 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2014 | 137 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 514 | 0.110 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2011 | 99 | 0.110 |
Why?
|
| Transplant Recipients | 1 | 2014 | 109 | 0.110 |
Why?
|
| Aortic Diseases | 1 | 2014 | 113 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2010 | 52 | 0.110 |
Why?
|
| Patient Discharge | 1 | 2015 | 294 | 0.110 |
Why?
|
| Cardiac Volume | 2 | 2009 | 21 | 0.110 |
Why?
|
| North America | 4 | 2015 | 112 | 0.110 |
Why?
|
| Immunologic Factors | 2 | 2010 | 87 | 0.110 |
Why?
|
| Survival Analysis | 5 | 2008 | 714 | 0.100 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2005 | 123 | 0.100 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 112 | 0.100 |
Why?
|
| Thoracic Arteries | 1 | 2011 | 10 | 0.100 |
Why?
|
| Aprotinin | 1 | 2011 | 55 | 0.100 |
Why?
|
| Growth Disorders | 1 | 2011 | 21 | 0.100 |
Why?
|
| Tranexamic Acid | 1 | 2011 | 37 | 0.100 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 69 | 0.100 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2014 | 47 | 0.100 |
Why?
|
| Antifibrinolytic Agents | 1 | 2011 | 52 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2011 | 1040 | 0.100 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 79 | 0.100 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 11 | 0.100 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2006 | 117 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 955 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 1026 | 0.090 |
Why?
|
| Pregnancy | 4 | 2010 | 2334 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2003 | 618 | 0.090 |
Why?
|
| Vascular Patency | 2 | 2015 | 122 | 0.090 |
Why?
|
| Cross-Over Studies | 2 | 2021 | 260 | 0.090 |
Why?
|
| Body Height | 1 | 2010 | 67 | 0.090 |
Why?
|
| Infant, Low Birth Weight | 3 | 2021 | 84 | 0.090 |
Why?
|
| Hospitals, Pediatric | 1 | 2011 | 114 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 940 | 0.090 |
Why?
|
| Miniaturization | 1 | 2010 | 21 | 0.090 |
Why?
|
| Heart Septal Defects | 1 | 2010 | 27 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2010 | 223 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 292 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 186 | 0.090 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2009 | 31 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2010 | 140 | 0.090 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2010 | 100 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2010 | 2223 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 581 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 86 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2011 | 150 | 0.080 |
Why?
|
| Birth Weight | 1 | 2010 | 186 | 0.080 |
Why?
|
| Diffusion of Innovation | 1 | 2009 | 102 | 0.080 |
Why?
|
| Intensive Care Units, Neonatal | 3 | 2013 | 113 | 0.080 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 223 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2008 | 99 | 0.080 |
Why?
|
| Antihypertensive Agents | 3 | 2019 | 498 | 0.080 |
Why?
|
| Atrial Appendage | 1 | 2007 | 1 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 319 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2022 | 867 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 2006 | 242 | 0.070 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2007 | 36 | 0.070 |
Why?
|
| Inflammation | 1 | 2013 | 1030 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 1851 | 0.070 |
Why?
|
| Infant Welfare | 2 | 2004 | 18 | 0.070 |
Why?
|
| Coronary Thrombosis | 1 | 2006 | 45 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2009 | 403 | 0.070 |
Why?
|
| Cardiac Output | 2 | 2019 | 133 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2007 | 123 | 0.070 |
Why?
|
| Heart Aneurysm | 1 | 2006 | 21 | 0.070 |
Why?
|
| Decision Making | 1 | 2009 | 410 | 0.070 |
Why?
|
| Manikins | 1 | 2006 | 42 | 0.070 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2020 | 98 | 0.070 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2006 | 38 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 506 | 0.070 |
Why?
|
| Vocal Cord Paralysis | 1 | 2005 | 18 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2006 | 108 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2020 | 238 | 0.060 |
Why?
|
| Aneurysm, False | 1 | 2006 | 60 | 0.060 |
Why?
|
| Decompression, Surgical | 1 | 2005 | 55 | 0.060 |
Why?
|
| Obesity | 2 | 2022 | 1076 | 0.060 |
Why?
|
| Prostheses and Implants | 1 | 2006 | 159 | 0.060 |
Why?
|
| Respiration, Artificial | 3 | 2013 | 190 | 0.060 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2006 | 186 | 0.060 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2006 | 164 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2004 | 17 | 0.060 |
Why?
|
| Aortic Valve | 1 | 2006 | 249 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2004 | 18 | 0.060 |
Why?
|
| Hyperventilation | 1 | 2004 | 6 | 0.060 |
Why?
|
| Cardiomyopathies | 1 | 2006 | 167 | 0.060 |
Why?
|
| Trisomy | 1 | 2004 | 47 | 0.060 |
Why?
|
| Fetal Diseases | 1 | 2004 | 64 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 1753 | 0.060 |
Why?
|
| Nitrogen Dioxide | 1 | 2003 | 13 | 0.060 |
Why?
|
| Disease Management | 1 | 2005 | 248 | 0.060 |
Why?
|
| Prostaglandins E | 1 | 2003 | 54 | 0.060 |
Why?
|
| Mass Screening | 1 | 2008 | 843 | 0.050 |
Why?
|
| Biopsy | 3 | 2015 | 540 | 0.050 |
Why?
|
| Systole | 2 | 2016 | 149 | 0.050 |
Why?
|
| Methadone | 1 | 2022 | 32 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 46 | 0.050 |
Why?
|
| Thrombosis | 2 | 2018 | 218 | 0.050 |
Why?
|
| Deglutition Disorders | 1 | 2005 | 297 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 649 | 0.050 |
Why?
|
| Infant, Extremely Premature | 1 | 2021 | 18 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 951 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 110 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2010 | 334 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 306 | 0.050 |
Why?
|
| Morbidity | 2 | 2013 | 130 | 0.040 |
Why?
|
| Larva | 1 | 2000 | 39 | 0.040 |
Why?
|
| Brazil | 1 | 2000 | 48 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2019 | 22 | 0.040 |
Why?
|
| Fluconazole | 1 | 2019 | 26 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2016 | 652 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 172 | 0.040 |
Why?
|
| Coronary Angiography | 2 | 2015 | 866 | 0.040 |
Why?
|
| Cineangiography | 1 | 1999 | 15 | 0.040 |
Why?
|
| Child Behavior | 1 | 2019 | 56 | 0.040 |
Why?
|
| Cyclic GMP | 1 | 1999 | 99 | 0.040 |
Why?
|
| Child Language | 1 | 2019 | 5 | 0.040 |
Why?
|
| Infant Behavior | 1 | 2019 | 12 | 0.040 |
Why?
|
| Creatinine | 1 | 2019 | 243 | 0.040 |
Why?
|
| Heart-Assist Devices | 1 | 2001 | 221 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2021 | 483 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 1999 | 99 | 0.040 |
Why?
|
| Nifedipine | 1 | 1998 | 40 | 0.040 |
Why?
|
| Phenotype | 2 | 2014 | 947 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2018 | 17 | 0.040 |
Why?
|
| Half-Life | 1 | 2018 | 96 | 0.040 |
Why?
|
| Primary Graft Dysfunction | 1 | 2017 | 12 | 0.040 |
Why?
|
| Lung | 1 | 2002 | 849 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2018 | 82 | 0.040 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2017 | 14 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 1998 | 164 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 117 | 0.040 |
Why?
|
| Electronic Mail | 1 | 2017 | 29 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2020 | 335 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 211 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2022 | 703 | 0.040 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 92 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2018 | 392 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 1996 | 42 | 0.030 |
Why?
|
| Anesthetics | 1 | 2016 | 30 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2018 | 186 | 0.030 |
Why?
|
| Registries | 2 | 2014 | 733 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 1996 | 81 | 0.030 |
Why?
|
| Reoperation | 2 | 2010 | 467 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2019 | 682 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 109 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 156 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 307 | 0.030 |
Why?
|
| Seizures | 1 | 2018 | 279 | 0.030 |
Why?
|
| Pyridones | 1 | 1995 | 40 | 0.030 |
Why?
|
| Motor Activity | 1 | 2019 | 621 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 152 | 0.030 |
Why?
|
| Medical Records | 1 | 2015 | 121 | 0.030 |
Why?
|
| Perfusion | 1 | 2015 | 131 | 0.030 |
Why?
|
| Permeability | 1 | 2015 | 131 | 0.030 |
Why?
|
| Calibration | 1 | 2015 | 73 | 0.030 |
Why?
|
| Cognition | 1 | 2019 | 513 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 139 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 381 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2014 | 178 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 296 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 256 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 2014 | 103 | 0.030 |
Why?
|
| Disease Progression | 2 | 2010 | 1038 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2013 | 117 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 517 | 0.030 |
Why?
|
| Factor VIIa | 1 | 2011 | 25 | 0.020 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 21 | 0.020 |
Why?
|
| Hospital Charges | 1 | 2011 | 60 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2012 | 74 | 0.020 |
Why?
|
| Collateral Circulation | 1 | 2011 | 34 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2012 | 101 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 72 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2011 | 133 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 1342 | 0.020 |
Why?
|
| Glycosides | 1 | 2010 | 14 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 786 | 0.020 |
Why?
|
| Aldosterone | 1 | 2010 | 51 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 38 | 0.020 |
Why?
|
| Diuretics | 1 | 2010 | 97 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 2010 | 138 | 0.020 |
Why?
|
| Stents | 1 | 2014 | 657 | 0.020 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2010 | 25 | 0.020 |
Why?
|
| Technology Transfer | 1 | 2009 | 7 | 0.020 |
Why?
|
| Amniocentesis | 1 | 2009 | 12 | 0.020 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2010 | 46 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 392 | 0.020 |
Why?
|
| Organizational Innovation | 1 | 2009 | 55 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 742 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 330 | 0.020 |
Why?
|
| Maternal Age | 1 | 2009 | 70 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 274 | 0.020 |
Why?
|
| Appetite | 1 | 2008 | 16 | 0.020 |
Why?
|
| Irritable Mood | 1 | 2008 | 15 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 201 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 626 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2008 | 32 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2008 | 26 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 242 | 0.020 |
Why?
|
| Arthralgia | 1 | 2008 | 30 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 500 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2010 | 233 | 0.020 |
Why?
|
| Diarrhea | 1 | 2008 | 63 | 0.020 |
Why?
|
| Vomiting | 1 | 2008 | 56 | 0.020 |
Why?
|
| Observer Variation | 1 | 2009 | 330 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2008 | 122 | 0.020 |
Why?
|
| Cough | 1 | 2008 | 65 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 371 | 0.020 |
Why?
|
| Leadership | 1 | 2009 | 136 | 0.020 |
Why?
|
| Cardiology | 1 | 2009 | 140 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2008 | 97 | 0.020 |
Why?
|
| Dextrocardia | 1 | 2007 | 4 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2007 | 21 | 0.020 |
Why?
|
| Animals | 2 | 2007 | 20881 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2007 | 5 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2007 | 53 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2009 | 322 | 0.020 |
Why?
|
| Angiography | 1 | 2007 | 194 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 133 | 0.020 |
Why?
|
| Fever | 1 | 2007 | 96 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 579 | 0.020 |
Why?
|
| Pharyngeal Diseases | 1 | 2005 | 21 | 0.020 |
Why?
|
| Laryngeal Diseases | 1 | 2005 | 22 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 1426 | 0.020 |
Why?
|
| Aspirin | 1 | 2007 | 295 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2006 | 291 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2005 | 20 | 0.020 |
Why?
|
| Sex Factors | 1 | 2008 | 1266 | 0.020 |
Why?
|
| Heart Valve Prosthesis | 1 | 2006 | 222 | 0.010 |
Why?
|
| Tricuspid Atresia | 1 | 2004 | 4 | 0.010 |
Why?
|
| Double Outlet Right Ventricle | 1 | 2004 | 4 | 0.010 |
Why?
|
| Tidal Volume | 1 | 2004 | 17 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1140 | 0.010 |
Why?
|
| Thrombectomy | 1 | 2006 | 238 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2007 | 448 | 0.010 |
Why?
|
| Europe | 1 | 2004 | 196 | 0.010 |
Why?
|
| Rhinitis | 1 | 2008 | 383 | 0.010 |
Why?
|
| Heart | 1 | 2008 | 850 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 157 | 0.010 |
Why?
|
| Aged | 1 | 1999 | 14862 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2002 | 23 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2003 | 86 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 168 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 2002 | 236 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2006 | 807 | 0.010 |
Why?
|
| Middle Aged | 1 | 1999 | 21147 | 0.010 |
Why?
|
| Waiting Lists | 1 | 2001 | 104 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 2001 | 368 | 0.010 |
Why?
|
| Acute Disease | 1 | 2001 | 658 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 772 | 0.010 |
Why?
|